JPRN-UMIN000031532招募中3 期
Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE III) - Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE III)
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 880 人开始时间: 2018年3月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 880
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancies 2) Infections which needs systemic treatment. 3) Body temperature is higher than 38 degrees centigrade at registration. 4) History of allergy aspirin or salicylic acid. 5) Female during pregnancy, within 28 days of postparturition, or during lactation. 6) Severe psychological disease. 7) Continuous systemic corticosteroid or immunosuppressant treatment. 8) Severe postoperative complicatoins which do not resolve until registration. 9) Regularly using phenytoin. 10) Uncontrollable diabetes mellitus. 11) Uncontrollable hypertension. 12) Unstable angina pectoris, or history of myocardial infarction within 6 months.
研究者
相似试验
进行中（未招募）
3 期
JCOG1503C: Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trialcolorectal cancerJPRN-jRCTs031180009TAKASHIMA Atsuo880
进行中（未招募）
1 期
Adjuvant aspirin treatment in PIK3CA mutated colon cancer patientsEUCTR2015-001482-57-BESAKK Swiss Group for Clinical Cancer Research185
进行中（未招募）
1 期
Adjuvant aspirin treatment in PIK3CA mutated colon cancer patientsEUCTR2015-001482-57-HUSAKK Swiss Group for Clinical Cancer Research185
进行中（未招募）
1 期
Adjuvant aspirin treatment in PIK3CA mutated colon cancer patientsEUCTR2015-001482-57-DESAKK Swiss Group for Clinical Cancer Research185
进行中（未招募）
不适用
Aspirin and colorectal cancer prevention. Exploring the platelet hypothesis of its mechanism of actioWe will perform this clinical study to address the hypothesis that low-dose aspirin given once daily is acting primarily by selectively acetylating platelet COX-1 and suppressing its activity throughout the 24-hour dosing interval.EUCTR2013-004269-15-ESInsituto Aragonés de Ciencias de la Salud